korrents

← People and their mental models

Alex Telford's mental models

3 claims Alex Telford made fit 2 mental models. Most often: Bottlenecks, Incentives. Everything they said here.

Models they name

Their own words name the idea.

Bottlenecks

A system moves only as fast as its narrowest point; speed up anything else and nothing changes.

Used by 88 others

A computational discovery platform does not make a biotech fast, because the thousand other steps of drug development are still the bottleneck.

  1. Alex Telford Writer on biotechnology and the economics of drug development Another challenge for Class II biotechs is that even if you have a nifty computational drug discovery platform, you are still often bottlenecked by the rest of the drug development process. It takes 1,000 (or more!) small steps to advance a drug through discovery, development, and past the regulators. A new breed of biotechatelfo.github.io · 17 Sept 2024All korrents from this piece
    Their wordsAnother challenge for Class II biotechs is that even if you have a nifty computational drug discovery platform, you are still often bottlenecked by the rest of the drug development process. It takes 1,000 (or more!) small steps to advance a drug through discovery, development, and past the regulators.

    ↗A new breed of biotechatelfo.github.io

    17 Sept 2024

The hard part of drug discovery is knowing what to make - which target is worth drugging - not designing the molecule.

  1. Alex Telford Writer on biotechnology and the economics of drug development The most significant factor preventing us from taking better molecules into clinical trials is not our ability to design arbitrary molecules, but our (lack of) understanding of underlying disease biology. In other words, we often know how to make something, but not what to make. The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about itatelfo.github.io · 23 Dec 2023All korrents from this piece
    Their wordsThe most significant factor preventing us from taking better molecules into clinical trials is not our ability to design arbitrary molecules, but our (lack of) understanding of underlying disease biology. In other words, we often know how to make something, but not what to make.

    ↗The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about itatelfo.github.io

    23 Dec 2023

Models we see in what they say

Our reading: their claim applies the idea without naming it. The claim is theirs; filing it here is ours.

Incentives

Look at what people are rewarded for; it explains more behaviour than what they say, your own included.

Used by 84 others

How long a trial takes decides which diseases get drugs at all, because capital flows to the indications whose endpoints can be measured quickly.

  1. Alex Telford Writer on biotechnology and the economics of drug development Because patents have fixed term lengths, with small extensions to compensate for the year or so when the drug is under regulatory review, drug developers are incentivized to go after conditions where clinical trials can be completed quickly, all else being equal. The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about itatelfo.github.io · 23 Dec 2023All korrents from this piece
    Their wordsBecause patents have fixed term lengths, with small extensions to compensate for the year or so when the drug is under regulatory review, drug developers are incentivized to go after conditions where clinical trials can be completed quickly, all else being equal.

    ↗The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about itatelfo.github.io

    23 Dec 2023